Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863792 | 0.90 | ESR1 (0.53) | ESR1LMNAKMT2AHPGDNR1I2 | |
| SCHEMBL5863852 | 0.88 | ESR1 (0.57) | ESR1LMNAKMT2AHPGDNR1I2 | |
| SCHEMBL5863848 | 0.81 | CCR3 (0.53) | ESR1 | |
| SCHEMBL5864358 | 0.81 | ESR1 (0.49) | ESR1LMNAKMT2AHPGDNR1I2 | |
| SCHEMBL5863885 | 0.80 | HTR7 (0.59) | ESR1LMNAKMT2AHPGDCNR2 | |
| SCHEMBL5864277 | 0.76 | ESR1 (0.53) | ESR1LMNAKMT2AHPGDNR1I2 | |
| SCHEMBL5863975 | 0.76 | ESR1 (0.55) | ESR1KMT2ANR1I2CNR2CNR1 | |
| SCHEMBL19850993 | 0.75 | L3MBTL1 (0.62) | KMT2AL3MBTL1KDM4E | |
| SCHEMBL7979173 | 0.75 | L3MBTL1 (0.62) | KMT2AL3MBTL1KDM4E | |
| SCHEMBL5864160 | 0.74 | ESR1 (0.56) | ESR1LMNAKMT2AHPGDNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | ESR1 4/4885LMNA 3627/4885KMT2A 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.